Separately, ValuEngine upgraded shares of DarioHealth from a strong sell rating to a sell rating in a research report on Friday, February 2nd.
DRIO opened at $1.72 on Monday. DarioHealth has a 12 month low of $1.32 and a 12 month high of $3.64. The firm has a market capitalization of $27.69, a P/E ratio of -1.05 and a beta of -1.75.
A hedge fund recently bought a new stake in DarioHealth stock. Anson Funds Management LP acquired a new stake in DarioHealth (NASDAQ:DRIO) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 105,071 shares of the company’s stock, valued at approximately $168,000. Anson Funds Management LP owned approximately 1.02% of DarioHealth as of its most recent SEC filing. Institutional investors and hedge funds own 1.67% of the company’s stock.
WARNING: This piece was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://dakotafinancialnews.com/2018/04/13/chardan-capital-begins-coverage-on-dariohealth-drio.html.
DarioHealth Company Profile
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. Its flagship product is Dario, a mobile, real-time, cloud-based, diabetes management solution based on a multi-feature software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device.
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.